Reuters: Valeant supporter Paulson grabs 6 million-plus Allergan shares

Carly Helfand

Tuesday, CEO J. Michael Pearson said his company was close to luring the 25% of investors it needs to call a special meeting, where it believes it can shake up 's board and dismantle its poison pill defense to make way for a takeover. And now, the Canadian pharma may have just picked up some more support.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS